



BMJ Open Prevalence of long COVID-19 among healthcare workers: a systematic review and meta-analysis protocol

Amani Al-Oraibi,^{1,2} Jatin Sridhar Naidu ,³ Aasiya Chaka,⁴ Katherine Woolf ,³ Laura B Nellums ,² Carolyn Tarrant,⁵ Daniel Pan,^{1,4} Shirley Sze,⁶ Christopher A Martin ,^{1,4} Mayuri Gogoi ,¹ Joshua Nazareth ,^{1,4} Manish Pareek^{1,4}

To cite: Al-Oraibi A, Naidu JS, Chaka A, *et al*. Prevalence of long COVID-19 among healthcare workers: a systematic review and meta-analysis protocol. *BMJ Open* 2022;**12**:e065234. doi:10.1136/bmjopen-2022-065234

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2022-065234>).

Received 07 June 2022

Accepted 20 November 2022



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Department of Respiratory Sciences, University of Leicester, Leicester, UK

²Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, UK

³Medical School, University College London, London, UK

⁴Department of Infection and HIV Medicine, University Hospitals of Leicester NHS Trust, Leicester, UK

⁵Department of Health Sciences, University of Leicester, Leicester, UK

⁶Department of Cardiovascular Sciences, University of Leicester, Leicester, UK

Correspondence to

Dr Manish Pareek;
manish.pareek@leicester.ac.uk

ABSTRACT

Introduction A proportion of those who survive the acute phase of COVID-19 experience prolonged symptoms, commonly known as long COVID-19. Given that healthcare workers (HCWs) face an elevated risk of acute COVID-19 compared with the general population, the global burden of long COVID-19 in HCWs is likely to be large; however, there is limited understanding of the prevalence of long COVID-19 in HCWs, or its symptoms and their clustering. This review will aim to estimate the pooled prevalence and the symptoms of long COVID-19 among HCWs infected with SARS-CoV-2 globally, and investigate differences by country, age, sex, ethnicity, vaccination status and occupation.

Methods and analysis A systematic review and meta-analysis will be conducted. Medline (via Ovid), CINAHL (via EBSCO), Embase (via Ovid), PsycINFO (via EBSCO), *OpenGrey* (grey literature) and *medRxiv* (preprint server) will be searched from the 31 December 2019 onward. All research studies and preprint articles reporting any primary data on the prevalence and/or the symptoms of long COVID-19 among adult HCWs will be included. Methodological quality will be assessed using the Joanna Briggs Institute Critical Appraisal Checklist for Studies Reporting Prevalence Data. Outcomes are anticipated to be the prevalence of long COVID-19 among HCWs around the world and trajectory of symptoms. Data synthesis will include random-effect meta-analysis for studies reporting prevalence data of long COVID-19 following SARS-CoV-2 infection among HCWs. The results will be presented with a 95% CI as an estimated effect across studies. Heterogeneity will be assessed using I² statistic. Where meta-analysis is inappropriate, a narrative synthesis of the evidence will be conducted.

Ethics and dissemination Ethical approval is not needed as data will be obtained from published articles. We will publish our findings in a peer-reviewed journal and disseminate the results of our review at conferences.

PROSPERO registration number CRD42022312781.

INTRODUCTION

COVID-19 has spread across the world causing over six million deaths and significant morbidity globally.¹ Evidence has emerged that some patients with COVID-19 experience

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ Our protocol outlines a novel systematic review and meta-analysis on the prevalence of long COVID-19 among healthcare workers globally.
- ⇒ Use of robust methods and the inclusion of grey literature (eg, preprints).
- ⇒ Results will inform urgently needed public health policies on long COVID-19.
- ⇒ Lack of consistency of terms related to ethnicity may be a barrier to stratification.
- ⇒ Definitions of long COVID-19 may vary as the topic is still evolving.

long-term symptoms and complications that extend beyond the acute phase of infection. This is now widely known as long COVID-19.² Symptoms of long COVID-19 include, but are not limited to: muscle weakness; loss of smell and taste; fatigue; ‘brain fog’; breathlessness; anxiety and depression.^{3–5} However, many of these more persistent symptom profiles are less well understood and researched than those experienced during the acute phase.⁶ The aetiology underlying the symptoms observed is also unclear.⁷ Many healthcare professionals have avoided making a single diagnosis, opting instead for multiple diagnoses including permanent damage to vital organs, postintensive care syndrome, postviral fatigue syndrome and continued COVID-19 syndrome.⁸ Healthcare workers (HCWs), particularly those from ethnic minorities, are at increased risk of COVID-19 infection and adverse outcomes. Finally, it is unclear whether or how ethnicity is related to long COVID-19.^{9 10}

The WHO defines long COVID as ‘occurring three months from the onset of COVID, with symptoms that last at least two months that cannot be explained by any alternative diagnosis’.¹¹ The National Institute for Health and Care Excellence (NICE) differ

in their definition and state long COVID to be ‘signs and symptoms that develop during or after the COVID infection persisting for 4–12 weeks or more, that cannot be explained by any other diagnosis’.² This definition produces two classifications: ‘ongoing symptomatic COVID’ from 4 to 12 weeks and ‘post-COVID syndrome’ from after 12 weeks.² Both definitions function as ‘exclusion criteria’ which could potentially lead to missed diagnoses of long COVID. Therefore, NICE recently proposed a more inclusive definition such as ‘signs and symptoms that continue or develop after acute COVID’ which include both ongoing symptomatic COVID and post-COVID-19 syndrome.¹²

Many ongoing research studies seek to understand the long-term impacts of SARS-CoV-2 infection better.^{13–15} However, available data so far have been heterogeneous and vulnerable to biases, preventing a precise definition or population risk stratification.¹⁶ Early data from the Office for National Statistics in the UK suggest a higher risk of long COVID-19 in females.^{17 18} Other risk factors include increasing age and body mass index.¹⁹ Individuals from ethnic minority groups are at higher risk of morbidity and mortality from acute COVID-19 compared with white groups.^{20 21} The Scientific Advisory Group for Emergencies in the UK attribute these differences to ethnic differences in SARS-CoV-2 exposure rates, susceptibility and vulnerability to disease, social factors, and consequences of pandemic control measures (eg, the impact of lockdowns on jobs).²² However, the prevalence and impact of long COVID-19 in people from ethnic minority groups remains unknown. Furthermore, the prevalence of long COVID-19 in HCWs has not been studied.^{23 24} This is of urgent public health importance, since HCWs will have much higher exposure to COVID-19 than the general population, and therefore have a higher risk of infection compared with those from the general population. Furthermore, there may be a higher degree of stress due to working throughout a pandemic which may exacerbate risk factors following acute infection for the development of long COVID-19.^{25–27} Finally, ethnic minority groups are also over-represented in healthcare institutions such as the National Health Service (NHS), UK and many HCWs emigrate to the UK from countries such as the Philippines, India, Jamaica and South Africa.²⁸ The prevalence and direct effects of long COVID-19 on the diverse NHS workforce, and indirect effects, such as impact on patient care, warrant further study.

In this systematic review and meta-analysis, we aim to estimate the pooled prevalence and identify the symptoms of long COVID-19 among HCWs infected with SARS-CoV-2 virus, globally. We will then stratify our results by country, age, sex, ethnicity, SARS-CoV-2 vaccination status and occupation.

Objectives

1. Estimate the pooled prevalence of long COVID-19 among HCWs with a history of SARS-CoV-2 infection globally.

2. Estimate the prevalence of long COVID-19 among HCWs infected with a history of SARS-CoV-2 infection globally.
3. Identify the symptoms (and their clustering) among HCWs with long-COVID-19.

METHODS

Protocol design and registration

The development and design of this study protocol was in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses Protocol (PRISMA-P)²⁹ as shown in online supplemental appendix I. This study protocol is registered with the International Registration of Systematic reviews (PROSPERO), a platform for the international registration of prospective systematic reviews (CRD42022312781).

Eligibility criteria

All peer-reviewed and preprint articles reporting any primary data on the prevalence and/or the symptoms of long COVID-19 following confirmed, probable or suspected SARS-CoV-2 infection among adult (≥ 16 years old) HCWs (clinical and non-clinical staff), worldwide such as mixed-method studies, observational studies (including cross-sectional studies, retrospective and prospective cohort studies), case-control studies, and randomised and non-randomised controlled trials will be included.

Following the NICE definition of post-COVID-19 syndrome, we define long-COVID in this review as persistent/prolonged (constant, fluctuating or relapsing) symptoms and/or functional disability following SARS-CoV-2 infection for equal to or more than 4 weeks from onset of symptoms or from time of diagnosis, in people where the infection is self-reported, clinically diagnosed, and/or diagnosed through a laboratory test. As definitions have varied and changed overtime, we will also include any study that defines/reports the condition as ‘long COVID-19’ or persistent symptoms following SARS-CoV-2 infection in addition to studies reporting symptoms that align with our definition (even if studies have not defined it as ‘long COVID-19’).

Qualitative study designs not reporting prevalence data, and secondary analysis (ie, systematic reviews), will be excluded. Correspondence pieces and articles about predictive modelling, basic science or using animal data will be excluded.

Information sources

The following databases will be searched for articles, from the 31 of December 2019 onward Medline (via Ovid), CINAHL (via EBSCO), Embase (via Ovid), PsycINFO (via EBSCO) and *medRxiv* (preprint server).

The reference lists of eligible articles will also be searched manually to identify additional relevant studies, not identified in the original database search.

Search strategy

The PRISMA-Search Reporting Extension (PRISMA-S)³⁰ and the Peer Review of Electronic Search Strategies Evidence-Based Checklist³¹ will be used to ensure the search strategy covers the review questions appropriately. A Boolean search strategy will be used with a combination of Medical Subject Headings and relevant text words to search systematically for relevant studies. The asterisk will be used for abridged terminology. Search terms have been created in consultation with the research team and a librarian to ensure that all relevant search terms are included, to develop a successful search strategy for each source of information and, therefore, to enhance the transparency and comprehensiveness of the review.³² Search terms were developed from reviewing relevant research, systematic reviews and reports. The search terms will be piloted several times to refine their sensitivity and specificity before the searches are conducted.

A detailed search terms and strategy table was developed for the four databases. Online supplemental appendix II details the database-specific search strategy for Medline. An alert will be set in for the databases to allow the reviewer (AA) to remain up to date with the medical literature currently being published.

Selection process

All studies identified using our search strategy will be independently assessed for eligibility through title and abstract screening, followed by a full-text screening, carried out by a minimum of two researchers and according to the PRISMA checklist.

Data items

For each eligible study, we will extract the following data using a structured piloted data extraction form in Microsoft Office Excel with the fields: title, author name(s), author contact details, year of publication, journal name, study design, country setting/context, data collection years (start date and end date), inclusion criteria, exclusion criteria, sample size (N), participant characteristics/demographics (eg, age, sex, ethnicity, occupational role, existing comorbidities, hospital (re)admission), symptoms of long COVID-19, cases of long COVID-19 (n), the prevalence of long COVID-19, and prevalence of long COVID-19 by age, sex, country, ethnicity and vaccination status.

Data collection process

Two researchers will undertake data extraction independently, and discrepancies will be identified and resolved through discussion with the whole research team, and a third reviewer will be involved if required. Missing data in selected studies will be requested from study authors, where possible.

Outcomes and prioritisation

Our primary outcome is the prevalence of long COVID-19 among HCWs around the world. We will be looking at differences in prevalence by age, sex, country, ethnicity

and vaccination status. Additional outcomes include (1) the nature and severity of long COVID-19 symptoms and their clustering and (2) the trajectory of the symptoms of long COVID-19.

Quality assessment

While extracting the data, the risk of bias will be assessed in relation to the review questions. The Joanna Briggs Institute critical appraisal checklist for prevalence studies will be used for each study which will enable us to distinguish between reliable studies, and studies with a strong possibility of bias, in the data synthesis stage. A discussion between the researchers will be conducted for any disagreements that occur during this process, and consensus will be achieved. Quality scores for the results of the assessment will be reported in a table. Studies will not be excluded on the basis of quality. However, sensitivity analyses will be carried out to examine the impact of study quality on the outcomes.

Data synthesis

A meta-analysis of the data will be carried out using Stata V.16.1 to calculate pooled estimates for the prevalence of long COVID-19 following SARS-CoV-2 infection among HCWs infected, globally. The results will be presented with a 95% CI as an estimated effect across studies. Heterogeneity will be assessed through the use of I² statistic.

Where appropriate, subgroup analysis will be carried out for the pooled prevalence of long-COVID in relation to country and ethnicity.

Patient and public involvement

No patients involved.

Twitter Amani Al-Oraibi @AmaniAlOraibi, Jatin Sridhar Naidu @JatinNaidu7 and Katherine Woolf @kathwoolf

Contributors AA-O, MP, KW, LN and CT designed the review. The protocol was drafted by AA-O, JN and AC. All authors read and approved the final protocol.

Funding This work was supported by the NHS Race and Health Observatory grant number (2122-59).

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Jatin Sridhar Naidu <http://orcid.org/0000-0001-9849-1976>

Katherine Woolf <http://orcid.org/0000-0003-4915-0715>

Laura B Nellums <http://orcid.org/0000-0002-2534-6951>

Christopher A Martin <http://orcid.org/0000-0002-2337-4799>

Mayuri Gogoi <http://orcid.org/0000-0002-9946-2509>

Joshua Nazareth <http://orcid.org/0000-0002-0603-9091>

REFERENCES

- 1 Johns Hopkins Coronavirus Resource Center. COVID-19 Map
- 2 NICE. COVID-19 rapid guideline: managing the long-term effects of COVID-19; 2020.
- 3 Huang C, Huang L, Wang Y, *et al.* 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet* 2021;397:220–32.
- 4 Goërtz YMJ, Van Herck M, Delbressine JM, *et al.* Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? *ERJ Open Res* 2020;6:00542-2020.
- 5 NHS. Long-term effects of coronavirus (long COVID)
- 6 Han Q, Zheng B, Daines L, *et al.* Long-term sequelae of COVID-19: a systematic review and meta-analysis of one-year follow-up studies on post-COVID symptoms. *Pathogens* 2022;11:269.
- 7 Akbarialiabadi H, Taghrir MH, Abdollahi A, *et al.* Long COVID, a comprehensive systematic scoping review. *Infection* 2021;49:1163–86.
- 8 Mahase E. Long covid could be four different syndromes, review suggests. *BMJ* 2020;371:m3981.
- 9 Ayoubkhani D, Khunti K, Nafilyan V, *et al.* Epidemiology of post-COVID syndrome following hospitalisation with coronavirus: a retrospective cohort study. *medRxiv* 2021.
- 10 Evans RA, McAuley H, Harrison EM, *et al.* Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. *Lancet Respir Med* 2021;9:1275–87.
- 11 The World Health Organization (WHO). A clinical case definition of post COVID-19 condition by a Delphi consensus, 2021. Available: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 [Accessed 29 Nov 2021].
- 12 NICE. COVID-19 rapid guideline: managing the longterm effects of COVID-19, 2022. Available: <https://www.nice.org.uk/guidance/ng188/resources/c>
- 13 Wu X, Liu X, Zhou Y, *et al.* 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. *Lancet Respir Med* 2021;9:747–54.
- 14 Riyahi S, Dev H, Behzadi A, *et al.* Pulmonary embolism in hospitalized patients with covid-19: a multicenter study. *Radiology* 2021;301:E426–33.
- 15 Tudoran C, Tudoran M, Pop GN, *et al.* Associations between the severity of the post-acute COVID-19 syndrome and echocardiographic abnormalities in previously healthy outpatients following infection with SARS-CoV-2. *Biology* 2021;10:469.
- 16 Michelen M, Manoharan L, Elkheir N, *et al.* Characterising long COVID: a living systematic review. *BMJ Glob Health* 2021;6:e005427.
- 17 Office for National Statistics (ONS). Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK - Office for National Statistics [Internet], 2021. Available: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/7october2021> [Accessed 29 Nov 2021].
- 18 Blomberg B, Mohn KG-I, Brokstad KA, *et al.* Long COVID in a prospective cohort of home-isolated patients. *Nat Med* 2021;27:1607–13.
- 19 Sudre CH, Murray B, Varsavsky T, *et al.* Attributes and predictors of long COVID. *Nat Med* 2021;27:626–31.
- 20 Yan BW, Hwang AL, Ng F, *et al.* Death toll of COVID-19 on Asian Americans: disparities revealed. *J Gen Intern Med* 2021;36:3545–9.
- 21 Office for National Statistics. Why have black and South Asian people been hit hardest by COVID-19? 2020.
- 22 GOV.UK. Drivers of the higher COVID-19 incidence, morbidity and mortality among minority ethnic groups executive summary; 2020.
- 23 Eiros R, Barreiro-Perez M, Martin-Garcia A, *et al.* Pericarditis and myocarditis long after SARS-CoV-2 infection: a cross-sectional descriptive study in health-care workers. *medRxiv* 2020.
- 24 Mattioli F, Stampatori C, Righetti F, *et al.* Neurological and cognitive sequelae of Covid-19: a four month follow-up. *J Neuro* 2021;268:4422–8.
- 25 Forte G, Favieri F, Tambelli R, *et al.* COVID-19 pandemic in the Italian population: validation of a post-traumatic stress disorder questionnaire and prevalence of PTSD symptomatology. *Int J Environ Res Public Health* 2020;17:4151–16.
- 26 Jiang HJ, Nan J, ZY L, *et al.* Psychological impacts of the COVID-19 epidemic on Chinese people: exposure, post-traumatic stress symptom, and emotion regulation. *Asian Pac J Trop Med* 2020;13:252.
- 27 Martin CA, Pan D, Melbourne C, *et al.* Predictors of SARS-CoV-2 infection in a multi-ethnic cohort of United Kingdom healthcare workers: a prospective nationwide cohort study (UK-REACH). *medRxiv* 2021.
- 28 Walton-Roberts M, Runnels V, Rajan SI, *et al.* Causes, consequences, and policy responses to the migration of health workers: key findings from India. *Hum Resour Health* 2017;15:1–18.
- 29 Moher D, Shamseer L, Clarke M. PRISMA-P. Nurul Fatiha Risma, Nor Azmaniza & Aniza. *Advances Bus Res Int Journal* 2021;196:224.
- 30 Rethlefsen ML, Kirtley S, Waffenschmidt S, *et al.* PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews. *Syst Rev* 2021;10:1–19.
- 31 Grösser SN. What Is a Validation Methodology? Analyzing and Synthesizing Two Meanings. In: *Systemic management for intelligent organizations*. Springer, 2012: 47–60.
- 32 O'Connor AM, Anderson KM, Goodell CK, *et al.* Conducting systematic reviews of intervention questions I: writing the review protocol, formulating the question and searching the literature. *Zoonoses Public Health* 2014;61 Suppl 1:28–38.

Appendix I: PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item	Page number
ADMINISTRATIVE INFORMATION			
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	2
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	Not applicable
Support:			
Sources	5a	Indicate sources of financial or other support for the review	8
Sponsor	5b	Provide name for the review funder and/or sponsor	
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	
INTRODUCTION			
Rationale	6	Describe the rationale for the review in the context of what is already known	2 & 3
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	3
METHODS			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting,	3

		time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	4
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	4
Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	5
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	5
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	5
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	5 & 6
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ)	
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication	5 & 6

	bias across studies, selective reporting within studies)	
Confidence in cumulative evidence	17 Describe how the strength of the body of evidence will be assessed (such as GRADE)	5&6

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.

Appendix II: Search Terms and Strategy for MEDLINE (via Ovid)

MEDLINE (via Ovid) from 1946 to 18 Feb 2022

Search ID #	Search terms	Results
1	(longcovid* or long covid* or longcoronavirus* or longcorona* virus* or long coronavirus* or long corona* virus* or longCov or long Cov or longsars* or long sars* or "long severe acute respiratory syndrome*" or longncov* or long ncov*).ti,ab,kw,kf.	929
2	((long* or endur* or legacy* or slow* or gradual* or protract* or lengthy* or chronic* or persist* or relaps* or remit* or remission* or residual* or delay* or prolong* or extend* or linger* or permanent* or fluctuat* or sequela* or multisystem* or "multi system*" or nonrecover* or "non recover*" or subacute* or "sub acute*" or lasting* or continuous* or continual* or continuing* or postacute* or "post acute*" or postdischarg* or "post discharg*" or postinfect* or "post infect*" or postviral* or "post viral*" or postvirus* or "post virus*") adj1 (covid* or coronavirus* or corona* virus* or Cov or "SARS-CoV-2*" or "SARSCoV-2*" or "SARSCoV2*" or "SARS-CoV2*" or "severe acute respiratory syndrome*" or Ncov* or "n-cov").ti,ab.	1,331
3	(("long* term*" or longterm* or "long* haul*" or longhaul* or "long* tail*" or longtail* or longduration* or "long duration*" or longlast* or "long last*" or longstanding* or "long standing*" or "medium* term*" or mediumterm*) adj3 (covid* or coronavirus* or corona* virus* or Cov or "SARS-CoV-2*" or "SARSCoV-2*" or "SARSCoV2*" or "SARS-CoV2*" or "severe acute respiratory syndrome*" or Ncov* or "n-cov").ti,ab.	980
4	((postcovid* or post covid* or postcoronavirus* or postcorona* virus* or post coronavirus* or post corona* virus* or	765

	postcoronavirinae* or postcorona* virinae* or post coronavirinae* or post corona* virinae* or postCov or post Cov or postsars* or post sars* or "post severe acute respiratory syndrome*" or postncov* or post ncov*) adj3 (syndrome* or disorder* or illness* or sickness* or disease* or condition* or symptom* or sign* or prognos* or followup* or "follow up*" or feature* or comorbid* or "co morbid*" or multimorbid* or "multi morbid*" or survivor* or survival* or risk* or care* or convalescen* or recuperat* or aftercare* or ambulatory* or outpatient* or "out patient*").ti,ab.	
5	((ongoing* or long* or endur* or legacy* or slow* or gradual* or protract* or lengthy* or chronic* or persist* or relaps* or remit* or remission* or residual* or delay* or prolong* or extend* or linger* or permanent* or fluctuat* or multisystem* or "multi system*" or nonrecover* or "non recover*" or subacute* or "sub acute*" or lasting* or continuous* or continual* or continuing* or postacute* or "post acute*" or postdischarg* or "post discharg*" or postinfect* or "post infect*" or postviral* or "post viral*" or postvirus* or "post virus*" or "medium* term*" or mediumterm*) adj4 (sequela* or illness* or symptom* or sign* or prognos* or rehab* or convalescen* or recuperat* or followup* or "follow up*" or feature*) adj10 (covid* or coronavirus* or corona* virus* or Cov or "SARS-CoV-2*" or "SARSCoV-2*" or "SARSCoV2*" or "SARS-CoV2*" or "severe acute respiratory syndrome*" or Ncov* or "n-cov").ti,ab.	2,369
6	((ongoing* or long* or endur* or legacy* or slow* or gradual* or protract* or lengthy* or chronic* or persist* or relaps* or remit* or remission* or residual* or delay* or prolong* or extend* or linger* or permanent* or fluctuat* or multisystem* or "multi system*" or subacute* or "sub acute*" or lasting* or continuous* or continual* or continuing* or post* or after* or follow* or "medium* term*" or mediumterm*) adj1 recover* adj10 (covid* or coronavirus* or corona* virus* or Cov or "SARS-CoV-2*" or "SARSCoV-2*" or "SARSCoV2*" or "SARS-CoV2*" or "severe acute respiratory syndrome*" or Ncov* or "n-cov").ti,ab.	687
7	or/1-6	4,958
8	exp coronavirus/	126,181
9	exp Coronavirus Infections/	152,493
10	(covid* or coronavirus* or corona* virus* or Cov or "SARS-CoV-2*" or "SARSCoV-2*" or "SARSCoV2*" or "SARS-CoV2*" or "severe acute respiratory syndrome*" or Ncov* or "n-cov").ti.	208,852

11	or/8-10	234,542
12	"Recovery of Function"/	57,919
13	Aftercare/	11,282
14	rehabilitation/	18,638
15	Activities of Daily Living/	69,497
16	convalescence/	3,879
17	convalescence/	789
18	Physical Functional Performance/	2,220
19	Physical Functional Performance/	159,088
20	11 and 19	1,037

21	("long* haul*" or longhaul* or "long* tail*" or longtail* or longduration* or "long duration*" or longlast* or "long last*" or longstanding* or "long standing*").ti,ab. and (8 or 9)	718
22	((recover* or nonrecover*) adj3 function* adj10 (covid* or coronavirus* or corona* virus* or Cov or "SARS-CoV-2*" or "SARSCoV-2*" or "SARSCoV2*" or "SARS-CoV2*" or "severe acute respiratory syndrome*" or Ncov* or "n-cov")).ti,ab.	80
23	((postacute* or "post acute*" or postdischarg* or "post discharg*" or postinfect* or "post infect*" or postviral* or "post viral*" or postvirus* or "post virus*" or subacute* or "sub acute*") adj3 (care* or convalescen* or recuperat* or aftercare* or ambulatory* or outpatient* or "out patient*" or survivor* or survival*) adj10 (covid* or coronavirus* or corona* virus* or Cov or "SARS-CoV-2*" or "SARSCoV-2*" or "SARSCoV2*" or "SARS-CoV2*" or "severe acute respiratory syndrome*" or Ncov* or "n-cov")).ti,ab.	68
24	((convalescen* or recuperat* or after* or followup* or "follow up*" or rehab*) adj1 (therap* or care*) adj10 (covid* or coronavirus* or corona* virus* or Cov or "SARS-CoV-2*" or "SARSCoV-2*" or "SARSCoV2*" or "SARS-CoV2*" or "severe acute respiratory syndrome*" or Ncov* or "n-cov")).ti,ab.	220
25	((ongoing* or endur* or long* or legacy* or slow* or gradual* or protract* or lengthy* or chronic* or persist* or relaps* or remit* or remission* or residual* or delay* or prolong* or extend* or linger* or permanent* or fluctuat* or multisystem* or "multi system*" or nonrecover* or "non recover*" or subacute* or "sub acute*" or lasting* or continuous* or continual* or continuing* or postacute* or "post acute*" or postdischarg* or "post discharg*" or postinfect* or "post infect*" or postviral* or "post viral*" or postvirus* or "post virus*" or "medium* term*" or mediumterm* or adverse* or dangerous* or harmful* or indirect* or injurious* or secondary* or side effect* or undesirable* or sequela* or complication* or consequence* or effect* or event* or impact* or outcome* or reaction* or complexit* or aftercare* or impair* or problem* or issue* or rehab* or function* or perform*) adj10 ((daily* or everyday* or day* or normal* or usual*) adj1 (activit* or living* or life* or lives* or job* or work* or employ* or occupation* or hobby* or hobbies* or leisure*)) adj10 (covid* or coronavirus* or corona* virus* or Cov or "SARS-CoV-2*" or "SARSCoV-2*" or "SARSCoV2*" or "SARS-CoV2*" or "severe acute respiratory syndrome*" or Ncov* or "n-cov")).ti,ab.	422
26	((ongoing* or endur* or long* or legacy* or slow* or gradual* or protract* or lengthy* or chronic* or persist* or relaps* or remit* or remission* or residual* or delay* or prolong* or extend* or linger* or permanent* or fluctuat* or multisystem* or "multi system*" or nonrecover* or "non recover*" or subacute* or "sub acute*" or lasting* or continuous* or continual* or continuing* or postacute* or "post acute*" or postdischarg* or "post discharg*" or postinfect* or "post infect*" or postviral* or "post viral*" or postvirus* or "post virus*" or "medium* term*" or mediumterm*) adj3 ((health* or adverse* or dangerous* or harmful* or indirect* or injurious* or secondary* or side* or undesirable* or negative* or damaging* or detriment* or abnormal*) adj3 (sequela* or complication* or consequence* or effect* or event* or impact* or outcome* or reaction* or complexit* or aftercare* or impair* or problem* or issue* or	289

	symptom* or disorder*)) adj10 (covid* or coronavirus* or corona* virus* or Cov or "SARS-CoV-2*" or "SARSCoV-2*" or "SARSCoV2*" or "SARS-CoV2*" or "severe acute respiratory syndrome*" or Ncov* or "n-cov")).ti,ab.	
27	((ongoing* or endure* or long* or legacy* or slow* or gradual* or protract* or lengthy* or chronic* or persist* or relaps* or remit* or remission* or residual* or delay* or prolong* or extend* or linger* or permanent* or fluctuat* or multisystem* or "multi system*" or nonrecover* or "non recover*" or subacute* or "sub acute*" or lasting* or continuous* or continual* or continuing* or postacute* or "post acute*" or postdischarg* or "post discharg*" or postinfect* or "post infect*" or postviral* or "post viral*" or postvirus* or "post virus*" or "medium* term*" or mediumterm*) adj3 ((physiolog* or neuro* or cardio* or gastro* or musculo* or renal* or kidney* or cognitive* or cognition* or rheumato* or dermatol* or skin* or haematol* or blood* or autonomic* or nervous* or nervous system* or otolaryngol* or laryngol* or otolog* or cerebro* or brain* or vascular* or respirator* or lung* or pulmonary* or psycholog* or mental health* or mental* or psychiatr* or exertion* or debilit* or devitali* or enervat* or drain* or sleep* or weak* or tired* or frail* or sapp* or strength* or confusion* or letharg* or fatigue* or tired* or weariness* or exhaust* or malaise* or pain* or headache* or breathless* or breathing* or myalgia* or delirious* or delirium* or appetite* or muscle* or muscular* or fitness* or memory* or stress* or depress* or anxiety* or emotion* or cough* or fever* or temperatur* or pneumon* or conjunctivit* or throat* or pharyngit* or dyspnea* or dyspnoea* or sick* or nausea* or nauseous* or vomit* or diarrhoea* or diarrhea* or taste* or anosmia* or smell* or olfact* or sweat* or dehydrat* or pyrexia* or nasal* or nose* or mucus* or ear* or hearing* or deaf* or "brain fog*" or cardiac* or thoracic* or chest* or ischemic* or ischaemic* or heart* or liver* or hepatic* or immuno* or palpitation* or vertigo* or metabol* or vestibular* or endocrine* or encephalit* or physical* or cough* or fibrosis* or myocarditis* or Guillain* or barre* or neuralgi* or amyotroph* or thrombo* or clot* or rash* or hive* or urticari* or lymph* or stroke* or TIA or toe* or foot* or feet* or finger* or chilblain* or numb* or inflammat* or inflame* or arthralgi* or eye* or organ or organs or tingl* or sting* or burn* or bladder* or urogenit* or genitourin* or genital* or reproducti* or urinary* or joint* or tachycard* or atrial* or autoimmun* or dysautonomi* or polyneuro* or mast* or mobility* or walking* or ambulation* or energy* or dizzy* or dizziness* or concentration* or abdominal* or abdomen* or anorexia* or anorexic* or sore* or tinnitus* or arrhythmia*) adj1 (sequela* or complication* or consequence* or effect* or event* or impact* or outcome* or reaction* or complexit* or aftercare* or impair* or problem* or issue* or symptom* or disorder* or abnormal*)) adj10 (covid* or coronavirus* or corona* virus* or Cov or "SARS-CoV-2*" or "SARSCoV-2*" or "SARSCoV2*" or "SARS-CoV2*" or "severe acute respiratory syndrome*" or Ncov* or "n-cov")).ti,ab.	559
28	((physiolog* or neuro* or cardio* or gastro* or musculo* or renal* or kidney* or cognitive* or cognition* or rheumato* or dermatol* or skin* or haematol* or blood* or autonomic* or nervous* or nervous system* or otolaryngol* or laryngol* or otolog* or cerebro* or brain* or vascular* or respirator* or lung* or pulmonary* or psycholog* or mental health* or mental* or psychiatr* or exertion* or	599

	<p>debilit* or devitali* or enervat* or drain* or sleep* or weak* or tired* or frail* or sapp* or strength* or confusion* or letharg* or fatigue* or tired* or weariness* or exhaust* or malaise* or pain* or headache* or breathless* or breathing* or myalgia* or delirious* or delirium* or appetite* or muscle* or muscular* or fitness* or memory* or stress* or depress* or anxiety* or emotion* or cough* or fever* or temperatur* or pneumon* or conjunctivit* or throat* or pharyngit* or dyspnea* or dyspnoea* or sick* or nausea* or nauseous* or vomit* or diarrhoea* or diarrhea* or taste* or anosmia* or smell* or olfact* or sweat* or dehydrat* or pyrexia* or nasal* or nose* or mucus* or ear* or hearing* or deaf* or "brain fog*" or cardiac* or thoracic* or chest* or ischemic* or ischaemic* or heart* or liver* or hepatic* or immuno* or palpitation* or vertigo* or metabol* or vestibular* or endocrine* or encephalit* or physical* or cough* or fibrosis* or myocarditis* or Guillain* or barre* or neuralgi* or amyotroph* or thrombo* or clot* or rash* or hive* or urticari* or lymph* or stroke* or TIA or toe* or foot* or feet* or finger* or chilblain* or numb* or inflammat* or inflame* or arthralgi* or eye* or organ or organs or tingl* or sting* or burn* or bladder* or urogenit* or genitourin* or genital* or reproducti* or urinary* or joint* or tachycard* or atrial* or autoimmun* or dysautonomi* or polyneuro* or mast* or mobility* or walking* or ambulation* or energy* or dizzy* or dizziness* or concentration* or abdominal* or abdomen* or anorexia* or anorexic* or sore* or tinnitus* or arrhythmia*) adj3 (postcovid* or post covid* or postcoronavirus* or postcorona* virus* or post coronavirus* or post corona* virus* or postcoronavirinae* or postcorona* virinae* or post coronavirinae* or post corona* virinae* or postCov or post Cov or postsars* or post sars* or "post severe acute respiratory syndrome*" or postncov* or post ncov*).ti,ab.</p>	
29	<p>((physiolog* or neuro* or cardio* or gastro* or musculo* or renal* or kidney* or cognitive* or cognition* or rheumato* or dermatol* or skin* or haematol* or blood* or autonomic* or nervous* or nervous system* or otolaryngol* or laryngol* or otolog* or cerebro* or brain* or vascular* or respirator* or lung* or pulmonary* or psycholog* or mental health* or mental* or psychiatr* or exertion* or debilit* or devitali* or enervat* or drain* or sleep* or weak* or tired* or frail* or sapp* or strength* or confusion* or letharg* or fatigue* or tired* or weariness* or exhaust* or malaise* or pain* or headache* or breathless* or breathing* or myalgia* or delirious* or delirium* or appetite* or muscle* or muscular* or fitness* or memory* or stress* or depress* or anxiety* or emotion* or cough* or fever* or temperatur* or pneumon* or conjunctivit* or throat* or pharyngit* or dyspnea* or dyspnoea* or sick* or nausea* or nauseous* or vomit* or diarrhoea* or diarrhea* or taste* or anosmia* or smell* or olfact* or sweat* or dehydrat* or pyrexia* or nasal* or nose* or mucus* or ear* or hearing* or deaf* or "brain fog*" or cardiac* or thoracic* or chest* or ischemic* or ischaemic* or heart* or liver* or hepatic* or immuno* or palpitation* or vertigo* or metabol* or vestibular* or endocrine* or encephalit* or physical* or cough* or fibrosis* or myocarditis* or Guillain* or barre* or neuralgi* or amyotroph* or thrombo* or clot* or rash* or hive* or urticari* or lymph* or stroke* or TIA or toe* or foot* or feet* or finger* or chilblain* or numb* or inflammat* or inflame* or arthralgi* or eye* or organ or organs or tingl* or sting* or burn* or bladder* or urogenit* or genitourin* or genital* or reproducti* or urinary* or joint* or tachycard* or atrial* or autoimmun* or dysautonomi* or polyneuro* or mast* or mobility* or walking* or ambulation* or energy* or</p>	2,453

	dizzy* or dizziness* or concentration* or abdominal* or abdomen* or anorexia* or anorexic* or sore* or tinnitus* or arrhythmia*) adj1 (sequela* or complication* or consequence* or complexit*) adj10 (covid* or coronavirus* or corona* virus* or Cov or "SARS-CoV-2*" or "SARSCoV-2*" or "SARSCoV2*" or "SARS-CoV2*" or "severe acute respiratory syndrome*" or Ncov* or "n-cov")).ti,ab.	
30	(((((multi or multiple* or overlap* or cluster* or numerous* or varied* or variety*) adj1 (symptom* or system* or disease* or disorder* or illness* or condition* or syndrome*)) or (multisymptom* or multisystem* or multidisease* or multidisorder* or multiillness* or multicondition* or multisyndrom*)) adj10 (covid* or coronavirus* or corona* virus* or Cov or "SARS-CoV-2*" or "SARSCoV-2*" or "SARSCoV2*" or "SARS-CoV2*" or "severe acute respiratory syndrome*" or Ncov* or "n-cov")) not ("Multisystem* inflammatory* syndrome*" or "inflammatory* multisystem* syndrome*")).ti,ab.	526
31	or/20-30	6,398
32	7 or 31	10,175
33	(physiotherapist* or (occupational adj therapist*) or (physical adj therapist*) or "medical professional*" or doctor* or physician* or clinician* or nurs* or midwif* or midwives or (health adj (professional* or worker* or staff* or practitioner*)) or (healthcare adj (professional* or worker* or staff* or practitioner*)) or paramedic* or "care professional*" or "front line").mp.	1,792,932
34	exp Health Personnel/	573,291
35	(radiographer* or "allied health professional*" or AHP or AHPs).mp.	7,273
36	((nhs or hospital) adj (staff or worker* or professional* or practitioner*)).mp.	8,189
37	exp medical staff/ or exp nursing staff/	93,971
38	((clean* or porter* or domestic) adj (staff or worker*)).mp.	707
39	(non-clinical adj (staff or worker* or workforce)).mp.	237
40	exp hospital personnel/	94,019
41	"healthcare assistant*".mp.	573
42	(cleaner* or porter*).mp.	7,817
43	Food Service, Hospital/	4,833

44	((hospital or healthcare or health) adj5 (porter* or clean* or domestic* or food* or catering* or cafeteria or canteen or restaurant) adj3 (staff or worker* or workforce)).mp.	518
45	or/33-44	1,995,021
46	32 and 45	1,366
47	limit 46 to yr="2019 – 2022"	1,354